The relationship between lopinavir plasma concentration and the magnitude of lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear. The aim of this study was to determine the relationship between drug concentration and lipid changes in two patient cohorts.
Methods
First, we analysed, in an outpatient cohort, the correlation between percentage lipid changes and lopinavir concentration, measured at least 2 weeks or more after initiation of lopinavir/ritonavir. Second, we analysed the correlation between lipid changes and lopinavir and ritonavir plasma concentrations in antiretroviral-naive patients enrolled in a trial comparing nevirapine plus lopinavir/ritonavir (533/133 mg twice daily) with zidovudine/lamivudine plus lopinavir/ ritonavir (400/100 mg twice daily).
Results
In 82 outpatients with 215 lopinavir plasma measurements, we found no significant correlations between lopinavir concentration and changes in lipids a median of 522 days after lopinavir/ritonavir initiation in univariable regression analyses, nor in multivariable analyses adjusting for potential confounders. In 40 trial samples collected 24 months after treatment initiation, the mean (95% CI) percentage increase in low-density lipoprotein cholesterol (LDLc) was significantly greater in the nevirapine/ lopinavir/ritonavir group (29.4% [16.8–43.3]) than in the zidovudine/lamivudine/lopinavir/ritonavir group (6.8% [-7.3–23.1]; P=0.03). However, the percentage LDLc change did not correlate with lopinavir or ritonavir concentration ratios (r=-0.25; P=0.17 and r=-0.06; P=0.75). Adding lopinavir or ritonavir concentrations into the multivariable regression analyses did not change the relation between LDLc change and randomized treatment.
Conclusions
Neither in an HIV outpatient clinic cohort nor in a trial comparing two lopinavir/ritonavir-containing therapies did we find any relation between changes in lipids, and lopinavir and ritonavir concentration, after initiating lopinavir/ritonavir-containing treatment.
References
1.
KempfD.J., KingM.S., BernsteinB.Incidence of resistance in a double-blind study comparing lopinavir/ ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis2004; 189: 51–60.
2.
MurphyR.L., da SilvaB.A., HicksC.B.Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials2008; 9: 1–10.
3.
van SighemA.I., GrasL.A., ReissP.Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS2010; 24: 1527–1535.
4.
SteinJ.H., KleinM.A., BellehumeurJ.L.Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation2001; 104: 257–262.
5.
D:A:D Study Group, Friis-MøllerN., ReissP., SabinC.A.Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356: 1723–1735.
6.
RhewD.C., BernalM., AguilarD.Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis2003; 37: 959–972.
7.
WormS.W., SabinC., WeberR.Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis2010; 201: 318–330.
8.
LeeG.A., SeneviratneT., NoorM.A.The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS2004; 18: 641–649.
9.
EronJ.Jr., YeniP., GatheJ.Jr.. The KLEAN study of fosamprenavir–ritonavir versus lopinavir–ritonavir, each in combination with abacavir–lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet2006; 368: 476–482.
10.
BreilhD., PellegrinI., RouzesA.Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS2004; 18: 1305–1310.
11.
KappelhoffB.S., CrommentuynK.M., de MaatM.M.Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet2004; 43: 845–853.
12.
ClevenberghP., GarraffoR., DellamonicaP.Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clin Trials2003; 4: 330–336.
13.
GutiérrezF., PadillaS., NavarroA.Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr2003; 33: 594–600.
14.
González de RequenaD., BlancoF., Garcia-BenayasT.Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS2003; 17: 443–445.
15.
LeónA., MartinezE., SarasaM.Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. J Antimicrob Chemother2007; 60: 824–830.
16.
TortiC., Quiros-RoldanE., Regazzi-BonoraM.Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. J Acquir Immune Defic Syndr2004; 35: 324–326.
ShafranS.D., MashinterL.D., RobertsS.E.The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med2005; 6: 421–425.
19.
PurnellJ.Q., ZambonA., KnoppR.H.Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS2000; 14: 51–57.
20.
Collot-TeixeiraS., De LorenzoF., WatersL.Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther2009; 85: 375–378.
21.
van VonderenM.G., van AgtmaelM.A., HassinkE.A.Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS ONE2009; 4: e5647.
22.
HsuA., IsaacsonJ., BrunS.Pharmacokinetic–pharmacodynamic analysis of lopinavir–ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother2003; 47: 350–359.
23.
FriedewaldW.T., LevyR.I., FredricksonD.S.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
24.
la PorteC.J., ColbersE.P., BertzR.Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother2004; 48: 1553–1560.
25.
TsengA., LoutfyM., PhillipsE.The relationship between lipid elevations and lopinavir (LPV) concentrations in HIV-infected patients on LPV/r-containing salvage regimens.42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 27–30 September 2002, San Diego, CA, USA. Abstract H-1916.
26.
BoffitoM., BonoraS., SiniccoA.Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir/ritonavir-containing regimens.4th International Workshop on Clinical Pharmacology of HIV Therapy. 27–29 March 2003, Cannes, France. Abstract 20.
27.
SteinJ.H.Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis2003; 45: 293–304.
28.
WaringJ.F., CiurlionisR., MarshK.Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Arch Toxicol2010; 84: 263–270.
29.
RiddlerS.A., SmitE., ColeS.R.Impact of HIV infection and HAART on serum lipids in men. JAMA2003; 289: 2978–2982.
30.
Dutch Association of Physicians in AIDS (NVAB) and the Dutch Institute for Health Care Improvement (CBO).Monitoring. In Guidelines on antiretroviral treatment in the Netherlands.Alphen aan de Rijn: Van Zuiden Communications BV2007; pp. 83–87.
31.
van der LeurM.R., BurgerD.M., la PorteC.J.A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit2006; 28: 650–653.
32.
TarrP.E., TelentiA.Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther2007; 12: 999–1013.
